Aethlon Medical (NASDAQ:AEMD) reported quarterly losses of $(0.16) per share which missed the analyst consensus estimate of $(0.13) by 23.08 percent. This is a 20 percent increase over losses of $(0.20) per share from the same period last year.
EF Hutton Initiates Coverage On PEDEVCO with Buy Rating, Announces Price Target of $2
EF Hutton analyst Ben Piggott initiates coverage on PEDEVCO (AMEX:PED) with a Buy rating and announces Price Target of $2.
